



CM HOSPITALAR S.A.

Publicly Traded Company

Corporate Taxpayer's ID (CNPJ/MF) 12.420.164/0001-57

Company's Registry (NIRE) 35.300.486.854

CVM Code 25682

ISIN: BRVVEOACNOR0

B3 Ticker: VVEO3

MATERIAL FACT

CM Hospitalar S.A. (**'Viveo'** or **'the Company'**), in compliance with Article 157, Paragraph 4, of the Brazilian Corporate Law (Law 6404 of December 15, 1976) and CVM Resolution 44 of August 23, 2021, hereby informs its stockholders and the market as follows: on May 31, 2022, pursuant to the share purchase agreement (**'the Agreement'**) signed on August 16, 2021, between **Viveo**, BPL Brazil Holding Company S.À.R.L (**'BPL Holding'**) and Profarma Distribuidora de Produtos Farmacêuticos S.A. (**'Profarma'**, and when jointly with BPL Holding, **'the Vendors'**), and following compliance with the conditions precedent specified in the Agreement, including acceptance of the transaction by the Brazilian antitrust authority, CADE, the parties completed acquisition by **Viveo** (**'the PFS Transaction'**) of (i) 100% of the unit shares in **BPL Brasil Participações Ltda.** and (ii) 100% of the share capital of **Cannes RJ Participações S.A.** – these two companies being direct or indirect holders of 100% of the shares in **Profarma Specialty S.A.**, **ARP Med S.A.**, **Amostra Medicamentos Hospitalares Ltda.**, **ARP Med Ltda.** and **Íntegra Medical Consultoria S.A.**, and referred to jointly herein as **'Profarma Specialty'**.

Profarma Specialty, founded in 2014, offers integrated solutions of distribution, specialty pharmacy products, and patient support services, with five distribution centers spread throughout Brazil and five specialized pharmacies, with focus on delivery – all of which now become part of the Viveo ecosystem.

The acquisition of Profarma Specialty further accelerates development of Viveo as an integrated system of products and services able to make a significant contribution to Brazil's health sector, through a supply chain that is more efficient and sustainable for all its stakeholders, from manufacturers to final clients.

As stated in the Material Announcement of August 16, 2021, the PFS Transaction does not include the interest in Profarma Distribuidora de Produtos Farmacêuticos S.A. held by AmerisourceBergen Corporation.

Ribeirão Preto, June 1, 2022

Flávia Carvalho
Investor Relations and M&A Officer